GlaxoSmithKline (GSK -0.1%) has agreed to support the production of the COVID-19 vaccine candidate developed by Novavax (NVAX -7.1%).
In an agreement reached with the U.S.-based vaccine developer and the UK Government Vaccines Taskforce, GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England for up to 60M vaccine doses for use in the U.K.
The transfer of technology is expected to begin immediately leading to production to start as early as May, GSK said in a statement.
Under an advance purchase agreement with Novavax, the U.K. government has secured 60M doses of the COVID-19 candidate which met its primary endpoint with an efficacy of 89.3% in a late-stage trial conducted in the country.
Picoteo ( aunque no me tocaba aún )
#127934
Re: Farmas USA
NVAX
Me ha pillado desconectado la noticia. Dejo el 5h quiero volver a entrar pero creo que aún le queda un poquito.
Le quedaría un cruce bajista MM20-MM50 y confirmar que aguanta la MM200. La voy a seguir de aquí a final de sesión.
#127935
Re: Farmas USA
KALA Reentro a $6.2.
Pequeña reentrada de DCPH a $40.97 y añado poquitas de TCRR a $21.77 y BPMC a $92.72.
Sin contar el exceso de NVAX la cartera estaría al 50% de cash.